Glenn J Hanna, Alessandro Villa, Shuvro P Nandi, Ruichao Shi, Anne ONeill, Mofei Liu, Charles T Quinn, Nathaniel S Treister, Herve Y Sroussi, Piamkamon Vacharotayangul, Laura A Goguen, Donald J Annino, Eleni M Rettig, Vickie Y Jo, Kristine S Wong, Patrick Lizotte, Cloud P Paweletz, Ravindra Uppaluri, Robert I Haddad, Ezra E W Cohen, Ludmil B Alexandrov, William N William, Scott M Lippman, Sook-Bin Woo
IMPORTANCE: Proliferative verrucous leukoplakia (PVL) is an aggressive oral precancerous disease characterized by a high risk of transformation to invasive oral squamous cell carcinoma (OSCC), and no therapies have been shown to affect its natural history. A recent study of the PVL immune landscape revealed a cytotoxic T-cell-rich microenvironment, providing strong rationale to investigate immune checkpoint therapy. OBJECTIVE: To determine the safety and clinical activity of anti-programmed cell death 1 protein (PD-1) therapy to treat high-risk PVL...
November 16, 2023: JAMA Oncology